TG Therapeutics
TGTX
$54.27
+7.34%
TG Therapeutics, Inc. is a fully integrated, commercial-stage biotechnology company focused on developing and commercializing novel treatments for B-cell diseases, with its lead product BRIUMVI (ublituximab-xiiy) approved for relapsing forms of multiple sclerosis (RMS). As a niche player in the MS treatment landscape, TG Therapeutics differentiates itself through its anti-CD20 monoclonal antibody therapy, which offers a differentiated dosing and efficacy profile. The current investor narrative centers on the company's rapid revenue growth from BRIUMVI, its path to sustained profitability, and its potential to expand into additional indications, while also facing scrutiny over its valuation and competitive positioning against larger MS players. Recent financial results show strong top-line growth and a transition to profitability, fueling optimism about the company's commercial execution and long-term market share gains.…
TGTX
TG Therapeutics
$54.27
Investment Opinion: Should I buy TGTX Today?
We rate TGTX as a Buy, driven by its exceptional revenue growth and improving profitability. The consensus 'Strong Buy' rating and average target price of $69.71 (28.5% upside) support this view. The company's Q1 2026 revenue growth of 69.6% YoY, net margin of 9.7%, and operating margin of 17.0% demonstrate strong operational execution. With a trailing PE of 9.6x and forward PE of 18.3x, the stock is reasonably valued for its growth prospects, especially considering the PEG ratio of 0.005. The main risks are competitive pressures and potential cash flow issues. If revenue growth decelerates below 30% or margins compress significantly, we would downgrade to Hold. Conversely, if the company achieves sustained profitability and expands indications, we could raise our target. Overall, TGTX appears undervalued relative to its growth potential, making it an attractive investment for growth-oriented investors.
Sign up to view all
TGTX 12-Month Price Forecast
The AI assessment leans bullish, driven by the company's exceptional revenue growth, improving profitability, and undemanding trailing valuation. However, the forward PE and competitive risks temper confidence. The key factor is whether the company can sustain its growth trajectory and expand margins. If revenue growth remains above 50% and the company achieves positive free cash flow, we would upgrade to high confidence. Conversely, any signs of deceleration or margin compression would prompt a downgrade to neutral.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on TG Therapeutics's 12-month outlook, with a consensus price target around $69.71 and implied upside of +28.5% versus the current price.
Average Target
$69.71
0 analysts
Implied Upside
+28.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$21 - $86
Analyst target range
Analyst coverage is limited but constructive, with 7 analysts covering the stock and a consensus recommendation of 'Strong Buy' (mean rating of 1.5). The average target price is $69.71, implying an upside of 28.5% from the current price of $54.27. The distribution includes 5 Buy ratings, 1 Hold, and 1 Underperform, indicating a generally bullish sentiment but with some caution. The high target of $86.00 suggests that some analysts see significant upside potential, likely based on continued revenue growth and potential label expansions, while the low target of $21.00 reflects concerns about competition or execution risks.
Bulls vs Bears: TGTX Investment Factors
TG Therapeutics presents a compelling bull case driven by explosive revenue growth, a transition to profitability, and a valuation that appears undemanding on trailing earnings. However, the forward PE of 18.3x and competitive pressures in the MS market introduce meaningful risks. The most critical tension is whether the company can sustain its growth trajectory and expand market share against larger, well-established competitors. If BRIUMVI continues to gain traction and the company achieves sustained profitability, the stock could re-rate higher. Conversely, any slowdown in growth or margin pressure could lead to multiple compression and a significant downside. Currently, the evidence slightly favors the bull case, given the strong fundamental momentum and analyst optimism, but investors should remain vigilant about execution risks.
Bullish
- Explosive Revenue Growth: Q1 2026 revenue surged 69.6% YoY to $204.9M, driven by BRIUMVI sales of $201.3M. Sequential growth from Q4 2025 ($192.6M) shows accelerating commercial momentum, indicating strong market adoption.
- Transition to Profitability: The company posted net income of $19.8M in Q1 2026, a sharp turnaround from $5.1M in Q1 2025. Operating margin expanded to 17.0% from 7.1% a year ago, demonstrating improving operational leverage.
- Undemanding Valuation: Trailing PE of 9.6x is low for a high-growth biotech, while forward PE of 18.3x implies significant earnings growth. PEG ratio of 0.005 suggests the stock is undervalued relative to its growth rate.
- Strong Analyst Conviction: Consensus rating is 'Strong Buy' with a mean score of 1.5. Average target price of $69.71 implies 28.5% upside, with the high target of $86.00 suggesting potential for substantial gains.
Bearish
- High Valuation on Forward Earnings: Forward PE of 18.3x may already price in aggressive growth expectations. Any earnings miss could trigger multiple compression, especially given the stock's beta of 1.67, which amplifies market volatility.
- Competitive Pressures in MS Market: BRIUMVI faces entrenched competitors like Ocrevus and Kesimpta. The low analyst target of $21.00 reflects concerns that market share gains may be slower than expected, potentially capping upside.
- Negative Free Cash Flow: TTM free cash flow is -$14.2M, indicating the company is still burning cash despite GAAP profitability. This could limit financial flexibility and increase reliance on external funding.
- Limited Analyst Coverage: Only 7 analysts cover the stock, which may lead to less efficient pricing and higher volatility. The presence of 1 Hold and 1 Underperform rating suggests not all analysts are convinced of the growth story.
TGTX Technical Analysis
TG Therapeutics is in a strong uptrend, with the stock price up 88.6% over the past year, significantly outperforming the S&P 500's 20.5% gain. The current price of $54.27 is near the upper end of its 52-week range, sitting at 91.5% of the range (calculated as (54.27-26.76)/(59.30-26.76)), indicating strong momentum and investor confidence. This positioning near the highs suggests the market is rewarding the company's growth trajectory, though it also raises the risk of overextension and potential profit-taking.
Beta
1.67
1.67x market volatility
Max Drawdown
-29.8%
Largest decline past year
52-Week Range
$27-$59
Price range past year
Annual Return
+88.6%
Cumulative gain past year
| Period | TGTX Return | S&P 500 |
|---|---|---|
| 1m | +3.0% | +3.6% |
| 3m | +39.6% | +2.7% |
| 6m | +83.8% | +11.4% |
| 1y | +88.6% | +18.7% |
| ytd | +85.3% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TGTX Fundamental Analysis
TG Therapeutics has demonstrated robust revenue growth, with Q1 2026 revenue of $204.9 million, up 69.6% year-over-year from $120.9 million in Q1 2025. This growth is accelerating, as sequential quarterly revenue increased from $192.6 million in Q4 2025 to $204.9 million in Q1 2026, and the company has consistently grown revenue from $73.5 million in Q2 2024 to the current level. The growth is driven by strong sales of BRIUMVI, which contributed $201.3 million in product revenue in Q1 2026, while license revenue added $3.6 million. This trajectory indicates a successful commercial launch and expanding market penetration, supporting the investment case for continued top-line expansion.
Quarterly Revenue
$204918000.0B
2026-03
Revenue YoY Growth
+69.6%
YoY Comparison
Gross Margin
83.7%
Latest Quarter
Free Cash Flow
$-14191000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TGTX Overvalued?
Given that TG Therapeutics is profitable with a trailing net income of $0.10 per share, the PE ratio is the most appropriate valuation metric. The trailing PE is 9.6x, while the forward PE is 18.3x, indicating that the market expects earnings to grow significantly in the coming year. The gap between trailing and forward PE suggests that the market is pricing in a substantial increase in earnings, which is consistent with the company's rapid revenue growth and improving margins. This forward multiple is reasonable for a high-growth biotech, but it also implies that any disappointment in earnings could lead to multiple compression.
PE
9.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 3x~96x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include the company's negative free cash flow of -$14.2M TTM, which indicates that despite GAAP profitability, cash generation is not yet positive. This could necessitate future capital raises or increased debt, though the current debt-to-equity of 0.40 and current ratio of 4.1 provide some cushion. Revenue concentration is high, with BRIUMVI accounting for 98% of Q1 2026 revenue, making the company vulnerable to any setback in that product's commercial performance. Additionally, the forward PE of 18.3x implies that the market expects significant earnings growth; any disappointment could lead to a sharp de-rating.
FAQ
The key risks include: 1) Competitive risk from established MS therapies like Ocrevus and Kesimpta, which could limit market share gains. 2) Financial risk from negative free cash flow of -$14.2M TTM, which may require future capital raises. 3) Execution risk in commercial expansion and pipeline development, as any setbacks could impact growth. 4) Valuation risk, as the forward PE of 18.3x implies high expectations; any earnings miss could lead to multiple compression. The most severe risk is a combination of slower growth and margin pressure, which could drive the stock down to the 52-week low of $26.76, a -50.7% decline from the current price.
The 12-month forecast is bullish, with a base case target of $60-$70 (45% probability), a bull case target of $70-$86 (35% probability), and a bear case target of $26-$40 (20% probability). The most likely scenario is the base case, where revenue growth continues at a robust but moderating pace, and the stock trades near the analyst average target of $69.71. The key assumption is that BRIUMVI continues to gain market share and the company maintains profitability. If growth accelerates or new indications are approved, the stock could reach the high target of $86. Conversely, competitive pressures or execution missteps could lead to a decline toward the low target.
Based on trailing earnings, TGTX appears undervalued with a PE of 9.6x, which is low for a company growing revenue at 69.6% YoY. However, the forward PE of 18.3x suggests the market is pricing in significant earnings growth, which may be justified given the company's trajectory. Compared to peers in the biotech sector, the valuation is reasonable, especially considering the PEG ratio of 0.005. The market is expecting continued strong growth and profitability, and if the company delivers, the stock could re-rate higher. Overall, the stock is fairly valued to slightly undervalued, with the potential for upside if growth continues.
TGTX appears to be a good buy for investors with a growth-oriented, higher-risk tolerance. The stock offers a 28.5% upside to the average analyst target of $69.71, and the trailing PE of 9.6x is attractive relative to its growth rate. However, the forward PE of 18.3x and competitive pressures in the MS market introduce risks. The biggest downside risk is a slowdown in revenue growth or margin compression, which could lead to a de-rating. For investors who believe in the long-term potential of BRIUMVI and the company's ability to expand its indications, TGTX could be a rewarding investment. It is not suitable for conservative investors seeking stable income or low volatility.
TGTX is more suitable for long-term investment, given its growth stage and the potential for multi-year expansion in the MS market and beyond. The company's revenue growth of 69.6% YoY and improving profitability suggest a strong fundamental trajectory, but the stock's beta of 1.67 and short ratio of 13.81 indicate high volatility, making it less suitable for short-term trading. Investors should be prepared for significant price swings and hold for at least 3-5 years to realize the full potential of BRIUMVI and pipeline developments. The company does not pay a dividend, so returns will come from capital appreciation. For those with a long-term horizon and risk tolerance, TGTX could be a rewarding addition to a diversified portfolio.